1. Home
  2. TKNO vs LCTX Comparison

TKNO vs LCTX Comparison

Compare TKNO & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alpha Teknova Inc.

TKNO

Alpha Teknova Inc.

N/A

Current Price

$4.87

Market Cap

308.3M

Sector

Health Care

ML Signal

N/A

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

N/A

Current Price

$1.03

Market Cap

301.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TKNO
LCTX
Founded
1996
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
308.3M
301.7M
IPO Year
2021
1996

Fundamental Metrics

Financial Performance
Metric
TKNO
LCTX
Price
$4.87
$1.03
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$6.25
AVG Volume (30 Days)
121.3K
949.6K
Earning Date
05-06-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
43.86
N/A
EPS
N/A
N/A
Revenue
$40,520,000.00
$14,556,000.00
Revenue This Year
$8.27
$109.40
Revenue Next Year
$13.13
N/A
P/E Ratio
N/A
N/A
Revenue Growth
7.35
53.24
52 Week Low
$1.91
$0.95
52 Week High
$6.68
$2.09

Technical Indicators

Market Signals
Indicator
TKNO
LCTX
Relative Strength Index (RSI) 42.61 28.68
Support Level $4.09 N/A
Resistance Level $4.94 $1.32
Average True Range (ATR) 0.37 0.06
MACD -0.10 -0.02
Stochastic Oscillator 13.98 7.04

Price Performance

Historical Comparison
TKNO
LCTX

About TKNO Alpha Teknova Inc.

Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.

Share on Social Networks: